The FDA has approved icotrokinra, an oral interleukin-23 receptor antagonist, for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or...
A study presented at the American College of Cardiology's 74th Annual Scientific Session found that GLP-1RA use in patients with psoriasis was linked to a lower incidence of major adverse cardiovascular...
A phase 3 trial evaluating apremilast in children and adolescents with moderate-to-severe plaque psoriasis showed improvements in disease severity compared with placebo over 16 weeks.
A recent phase 3b long-term extension study assessed the safety and efficacy of deucravacitinib over 2 years in patients with moderate-to-severe plaque psoriasis.
Despite being approved for use, consensus among the real-world data on the use of IL-23 inhibitors in psoriatic disease has been lacking; therefore, researchers recently examined the drug survival and...
In a post hoc analysis of the EXCEED study, researchers found that secukinumab and adalimumab—two biologic disease-modifying antirheumatic medications—showed similar efficacy in the resolution of enthesitis...
The authors of a recent study aimed to determine if the use of routine ultrasound could be an effective tool for screening patients with psoriasis for subclinical psoriatic arthritis.
